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ABSTRACT
Allogeneic hematopoietic cell transplantation (allo-HCT) may prolong life and cure patients suffering from
otherwise fatal diseases. However, the growing population of long-term survivors has led to the realization of
multiple long-term complications, including the risk of second malignancies. Compared to the autologous
setting, allo-HCT carries a much higher risk of posttransplant lymphoproliferative disorder (PTLD), which
usually occurs within the first year after allo-HCT and is strongly associated with the Epstein-Barr virus (EBV).
Treatment-related myelodysplastic syndromes (tMDS) and second leukemias are extremely rare. Both autol-
ogous and allo-HCT carry increased risks for second solid malignancies (SSM). The cumulative incidence of
SSM continues to increase in each of the largest studies with as much as 20 years of follow-up, likely related
to the long latency of radiation-related SSM. Systematic, prospective monitoring, vigilant screening processes,
and well-maintained survivorship clinics and databases are absolute necessities, and should be included in the
infrastructure of individual transplant centers and networks, with mandatory periodic reporting of second
malignancy incidences. Primary care and transplant physicians alike must be aware of the risk of second
malignancies after allo-HCT. Most importantly, guidelines should be developed in regard to screening and
prevention of second malignancies, so that physicians can provide state-of-the-art counsel and care for the
benefit of our patients.
© 2007 American Society for Blood and Marrow Transplantation
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There are almost 10 million cancer survivors in
he United States, representing 3.5% of the popula-
ion. This number has tripled since 1971, and is grow-
ng at approximately 2% per year [1,2]. For many
ematologic diseases the treatment with greatest po-
ential for cure includes an allogeneic (matched sibling
r unrelated donor-derived) hematopoietic cell trans-
lant (allo-HCT). The National Marrow Donor Pro-
ram (NMDP) has facilitated unrelated HCT in
5,000 patients since 1987, and currently averages
ore than 220 per month [3]. The improvement in
ancer survival comes with the realization of many
otential long-term effects and complications of treat-
ent. One of the most devastating long-term compli-
ations is the development of a second malignancy.
econd or higher order cancers accounted for 16% of nancer diagnoses in 2003, an incidence that has dou-
led over the last 20 years [4,5]. Second malignancies
re well described after treatment and exposure to
adiation [6-9], certain chemotherapy agents [10-12],
nd in a variety of disease settings including treatment
or Hodgkin disease [13,14]. Children particularly
ay be at increased risk secondary to their long life
xpectancy and potentially increased sensitivity of
roliferating tissue to carcinogens [13-21]. With the
rowing number of patients treated for hematologic
iseases surviving long term and possibly being cured,
he risk of developing second malignancies after allo-
CT has been increasingly recognized over the past 2
ecades [22-44]. The largest studies of second malig-
ancies after allo-HCT are listed in Table 1. There
re multiple factors possibly involved in second malig-
ancy in the allo-HCT setting, including cytotoxic che-
1121
Table 1. Large Studies of Second Malignancy after Allogeneic HCT
Study Setting No. pts
Median Time
to Malig
(Years)
Median Age
(Years) at
Trans Median f/u (Years) Relative Risk
Cumulative Incidence
of New
Second Malignancy
Gallagher, 2007 (multi-institution,
British Columbia)
Second solid malignancies
after allogeneic
transplant 1985-2003
926 6.8 39 1.8 1.85* 2.3% at 10 years*
Baker, 2003 (single institution,
U Minnesota)
Second malignancies after
autologous and
allogeneic transplant
1974-2001
3372 (2179 allo) NR 24 5 8.1* (auto
and allo)
6.9% at 20 years*
(auto and allo)
Bhatia 2001 (single institution,
City of Hope)
Second solid malignancies
after autologous and
allogeneic transplant
1976-1998
2129 (1370 allo) NR 33.9 3.3 (3.6 > 1 year
survival)
2.1* (auto
and allo)
6.4% at 10 years for
allogeneic subset
Socie, 2000 (multi-institution,
international bone marrow
transplant registry/U Wash)
Second malignancies after
allogeneic transplant
for childhood acute
leukemia (<age 17)
1964-1992
3,182 6 8.2 0.9 (3.6 > 1 year
survival)
45.1* 11% at 15 years (solid
tumors) 1% at 5
years (PTLD)
Kolb, 1999 (multi-institution, Late
Effects Working Party-Europe)
Second malignancies in
long-term survivors (>5
years) after allogeneic
and autologous
transplant before 1986
1036 (982 evaluable) (903 allo) NR 21 10.7 years 3.8 12.8% at 15 years
Curtis, 1999 (multi-institution,
international bone marrow
transplant registry/U Wash)
PTLD after allogeneic
bone marrow
transplantation 1964-
1992
18,014 NR 25 NR 51.5 1% at 10 years
Curtis, 1997 (multi-institution,
international bone marrow
transplant registry/U Wash)
Second solid malignancies
after allogeneic and
syngeneic transplant
1964-1992
19,229 (18,696 allo) NR 25.5 3.5 years 2.7* 8.3 for
>10 year
survivors
6.7% at 15 years*
Witherspoon, 1989 (single
institution, U Wash)
Second malignancies after
allogeneic and
autologous transplant
for leukemia or aplastic
anemia 1970-1987
2246 (1993 allo) 1.0 NR NR 6.69* (auto
and allo)
1.6% at 18 years*
ALLO indicates allogeneic; AUTO, autologous; PTLD, posttransplant lymphoproliferative disorder.
*Excluding nonmelanoma skin cancer as not recorded in SEER database.
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Second Malignancies after allo-HCT 1123otherapy, radiation, immunosuppressive therapy, im-
une stimulation, immune suppression from graft-
ersus-host disease (GVHD), antigenic stimulation,
ncogenic virus activity, and genetic predisposition [30].
e will describe these second malignancies after allo-
CT by dividing them into posttransplant lymphopro-
iferative disorders (PTLD), hematologic malignancies,
nd second solid malignancies (SSM).
osttransplant Lymphoproliferative Disorders
Posttransplant lymphoid neoplasms were ﬁrst rec-
gnized in 1969 in the setting of solid organ trans-
lantation [45,46]. PTLD is relatively common in
rgan transplantation with an incidence of 1%-20%,
epending on the type of allograft [47]. Initially it was
elt that PTLD was universally malignant, but it is
ow recognized that PTLD is a diverse group of
isorders ranging from benign self-limited polyclonal
yperplasias to clonal malignancies [48-52]. Histori-
ally, PTLD has been attributed to uncontrolled pro-
iferation of the Epstein-Barr virus (EBV) transformed
-lymphocytes; however, EBV negative PTLD has
lso been recognized [53]. PTLD also occurs after
ematopoietic cell transplantation (HCT), although
he entity is observed almost entirely following allo-
CT [25,27,29,42]. PTLD has been reported after
mbilical cord [54-56] and nonmyeloablative allo-
CT [56,57].
lassification
Before PTLD was deﬁned, posttransplant lym-
hoid neoplasms were classiﬁed as immunoblastic sar-
omas. Frizzera et al. [58] in 1987 appreciated certain
olymorphic morphologic changes in renal transplant
atients and introduced a classiﬁcation distinguishing
onspeciﬁc hyperplasia, polymorphic hyperplasia, and
olymorphic lymphoma from immunoblastic sar-
oma. In 1988, Nalesnik et al. [59] combined the
revious descriptions under the heading of polymor-
hic PTLD [59]. Monomorphic PTLD was also in-
roduced, and was felt to be indistinguishable from
on-Hodgkin lymphomas (NHL). However, mor-
able 2. World Health Organization Classiﬁcation of PTLD
Type Clonality
arly lesions Polyclonal U
a) Reactive lymphoplasmacytic
hyperplasia
b) Infectious mono-like lesions
olymorphic PTLD Mostly Polyclonal V
onomorphic PTLD Monoclonal S
odgkin Lymphoma and Hodgkin
lymphoma like PTLD
Monoclonal S
TLD indicates posttransplant lymphoproliferative disorder.hology alone does not provide reliable prognostic enformation. Knowles et al. [60] used morphology in
ombination with molecular genetic analysis in order
o evaluate clonality. PTLD was then reclassiﬁed into
olyclonal plasmacytic hyperplasia, monoclonal poly-
orphic B-cell hyperplasia or lymphoma, and mono-
lonal pleomorphic immunoblastic lymphoma or mul-
iple myeloma.
In 1995, the City of Hope National Medical Cen-
er in Duarte, CA, hosted the Society for Hematopa-
hology workshop on immunodeﬁciency-related lym-
hoproliferative disorders. Eighty-two cases from
ifferent settings; including posttransplant immunosup-
ression, other iatrogenic immunosuppression, congen-
tal immunodeﬁciencies, and the acquired immune
eﬁciency syndrome, were reviewed. This led to discus-
ions that culminated in the 1997 Society for Hema-
opathology classiﬁcation including (1) early lesions,
2) polymorphic PTLD, (3) PTLD-monomorphic, (4)
lasmacytoma-like lesions, and (5) T cell-rich large B
ell lymphoma/Hodgkin disease like lesions [61]. This
as the ﬁrst classiﬁcation system that appreciated the
linical differences between early and late PTLD.
In 2001, the World Health Organization (WHO)
ublished a revised PTLD classiﬁcation, which is
ost commonly used today. This includes (1) early
esions such as reactive lymphoplasmacytic hyperpla-
ia and infectious mononucleosis like lesions, (2) poly-
orphic PTLD, (3) monomorphic PTLD, and (4)
odgkin lymphoma (HL) and Hodgkin lymphoma-
ike PTLD (Table 2) [62].
pidemiology
The incidence of PTLD in allogeneic bone mar-
ow transplantation has been reported as between
.5% and 1.8%, with the majority occurring within
he ﬁrst year after transplantation [25,27,29,32,42,63].
TLD may be asymptomatic, and diagnosed only at
utopsy [25]. EBV is more prevalent in early PTLD,
nd is found in 90% of B cell PTLD within the ﬁrst
ear after transplantation. The proportion of EBV
egative disease increases in late (1 year) PTLD and
Characteristics
regress spontaneously or after reduction of immunosuppression
response to reduction of immunosuppression
e classified according to WHO classification of non-Hodgkin
oma
to Hodgkin lymphoma though controversy remains regarding
ttersually
ariable
hould b
lymph
imilar
the lancompasses 21% to 32% of cases overall [64].
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T. Lowe et al.1124The largest retrospective review to date of PTLD
fter allo-HCT included 18,014 patients from 234
enters reporting to the International Bone Marrow
ransplant Registry (IBMTR) and the Fred Hutchin-
on Cancer Research Center between 1964 and 1992
29]. The cumulative incidence of PTLD was 1% at
0 years. Fifty-eight percent of PTLD occurred
ithin 1-5 months, and 82% occurred before 1 year.
tiology
Primary EBV infection after transplantation is the
reatest risk factor in solid-organ PTLD, with a 10- to
6-fold increased risk of PTLD [47,64-67]. EBV, the
tiologic agent of infectious mononucleosis, is a mem-
er of the human herpes virus family [64,68]. In im-
unocompetent hosts it is transmitted via body ﬂuids
uch as saliva. More than 90% of the population has
mmunity to EBV by the age of 40, and it usually
stablishes life-long viral latency after primary infec-
ion. The immunocompetent host has several mecha-
isms to control EBV proliferation after primary in-
ection including cytotoxic T cell response, and to a
esser extent humoral immune response, natural killer
ctivity, and cytokine regulation [63,69-73]. The
ransmission of EBV in the transplant population oc-
urs mainly from blood products, but the transmission
ate is unknown. Although the pathophysiology is still
nclear, B cell PTLD is thought to be related to
actors that stimulate B cell proliferation and depress
BV-speciﬁc control mechanisms [74].
isk Factors
In addition to EBV infection, a number of other risk
actors have been identiﬁed (Table 3) [25,27,29,32,42].
ommon risk factors include HLA disparity (relative
isk [RR] 3.8-9.0), T cell depletion of the graft (RR
.0-12.7), use of antithymocyte globulin (ATG) in the
reparative regimen or GVHD prophylaxis (RR 3.1-
.4), and GVHD (RR 1.9-6.5). Use of anti-CD3
onoclonal antibody (mAb) was associated signiﬁ-
antly with PTDL in 2 studies [29,42]. In regard to T
ell depletion of the graft, Curtis et al. [29] found that
he methods applied for T cell depletion were rele-
ant: speciﬁcally, sheep red blood cell E-rosetting
echniques (RR 15.6) and mAb-based depletion of T
ells (RR 12.3) were associated with an increased risk
f early onset PTLD. As for development of late onset
TLD (1 year), Curtis et al. [29] only identiﬁed
hronic GVHD (cGVHD) as a signiﬁcant risk factor.
revention
Perhaps the best management of PTLD is preven-
ion by addressing the known risk factors. Although
VHD may be better controlled with T cell depletion
f donor grafts, ATG, and the use of anti-CD-3 an-
ibodies, the increased risk of PTLD must also be tecognized. The risk factor for PTLD well-described
n the solid transplant literature is development of new
BV infection in seronegative patients, and is largely
rom blood transfusions [64-67]. Hence, testing for
BV immunity status should be considered in allo-
CT candidates. In one study, leukoreduction of
acked red blood cells rendered 13 of 14 EBV-positive
nits negative by PCR [75]. There are no studies to
ate on whether this type of intervention translates to
linical beneﬁt. CMV immunity is routinely tested as
art of standard practice before allo-HCT, and CMV
nfection has also been implicated as a cofactor in solid
rgan PTLD.
Rituximab appears to be active in treatment of
BV reactivation after allo-HCT, and therefore, in
he prevention of PTLD. A prospective study from
he Netherlands in 2002 monitored 49 matched sib-
ing or matched unrelated donor T cell-depleted allo-
CT patients [76]. EBV quantitative real-time PCR
as measured weekly. Preemptive therapy with a sin-
le dose of rituximab was given in patients with
ore than 1000 copies/mL. Median time to pre-
mptive therapy in 15 patients was 113 days (range:
1-202 days) after allo-HCT. Fourteen patients had
complete response by quantitative EBV PCR. One
atient progressed to PTLD but obtained a com-
lete response with 2 doses of therapeutic rituximab
nd donor lymphocyte infusion. Notably, Wein-
tock et al. [77] published a comprehensive review
f the preemptive diagnosis and treatment of EBV-
ssociated PTLD in 2006.
At the City of Hope, we monitor for EBV reacti-
ation in “high risk” patients such as those treated
ith thymoglobulin. EBV quantitative PCR is evalu-
ted weekly starting at 21 days after allo-HCT. A
ingle dose of rituximab is given for EBV levels1000
opies/mL. Response is measured by quantitative
CR for at least 6 weeks after the infusion. If the level
emains 1000 copies/mL thereafter, 3 additional
oses of rituximab are given for a total course of 4
oses. EBV titers 1000 copies/mL at 6 weeks are
onitored weekly until the titer returns to baseline.
cell-depleted and mismatched donor grafts are not
ommonly used, but both have been identiﬁed as also
igh-risk factors for PTLD after allo-HCT (Table 3).
The use of anti-EBV agents, such as acyclovir or
anciclovir, is also of interest. Ganciclovir has the
reatest activity against EBV in vitro, but increased
yelosuppression may be of concern [78]. Several
ingle institutional reports suggest some efﬁcacy in
revention of PTLD [79-81]; however, contradictory
eports exist [82,83]. A recent multicenter case-con-
rol study of ganciclovir or acyclovir in renal trans-
lant patients demonstrated an 83% reduction in the
isk of PTLD with the former showing better efﬁcacy
84]. Finally, early studies of infusion of EBV-cyto-
oxic T cells have also shown efﬁcacy in decreasing
Table 3. Studies of PTLD after Allogeneic HCT
Study Setting
Number of
Patients
Median Time to
PTLD (Years)
Cumulative Incidence of
New PTLD
Relative
Risk
Significant Risk Factors (Excluding
Primary Immunodeficiency)
Baker, 2003 (single institution,
U Minnesota)
Second malignancies after
autologous and
allogeneic transplant
1974-2001
3372 (2179 allo) 0.3 (auto and allo) 1.4% at 20 years (71% of
pts <1 year) All but 1
in allo BMT
54.3 -Mismatched related donor (RR 9.0)
-T cell depletion (RR 4.0)
-Use of ATG for aGVHD (RR 3.7)
-Grade 3-4 aGVHD (RR 2.4)
Socie, 2000 (multi-institution,
international bone marrow
transplant registry/U Wash)
Second malignancies after
allogeneic transplant
for childhood acute
leukemia (<age 17)
1964-1992
3182 allo Unknown (1.5
years in text;
however, 75% of
pts <1 year in
table)
0.6% at 15 years (75% of
pts <1 year)
182 -Unrelated or mismatched related
donor (RR 7.5)
-Mod-severe GVHD (RR 6.5)
-T cell depletion of graft (RR 4.8)
-Use of ATG for aGVHD (RR 3.1)
Curtis, 1999 (multi-institution,
international bone marrow
transplant registry/U Wash)
PTLD after allogeneic
bone marrow
transplantation
1964-1992
18,014 allo 0.2-0.3 1% at 10 years (82% of
pts <1 year)
51.5 Early Onset PTLD (<1 year)
-Use of anti-CD3 mAb for aGVHD
(RR 43.2)
-T cell depletion of graft (RR 12.7)
-Use of ATG for aGVHD (RR 6.4)
-Unrelated or mismatched related
donor (RR 4.1)
-aGVHD grades II-IV (RR 1.9)
-Late-onset PTLD (>1 year)
-Extensive cGVHD (RR 4.0)
Witherspoon, 1989 (single
institution, U Wash)
Second malignancies after
allogeneic and
autologous transplant
for leukemia or aplastic
anemia 1970-1987
2246 (1993 allo) 0.2 0.7% at 18 years (auto
and allo) (75% of pts
<1 year)
355 -Use of anti-CD3 mAb for aGVHD
(RR 15.6)
-T cell depletion of graft (RR 12.4)
-Use of ATG for aGVHD (RR 4.9)
-Mismatch donor (RR 3.8)
mAb, indicates monoclonal antibody; ALLO, allogeneic; ATG, antithymocyte globulin; AUTO, autologous; GVHD, graft-versus-host disease; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease; HCT, hematopoietic cell transplantation; PTLD, posttransplant lymphoproliferative disorder; TBI, total-body irradiation; RR, relative risk; pts, patients.
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T. Lowe et al.1126iral loads, and may turn out to be useful in preventing
nd ameliorating EBV-related PTLD [85-87].
reatment
There have been no randomized trials of treat-
ent of PTLD. However, some recommendations
ay be made based on the WHO classiﬁcation [62].
he clinical utility of the WHO classiﬁcation system
as been veriﬁed by at least 1 study [88]. Type I or early
olyclonal lesions, which include reactive lymphoplas-
acytic hyperplasia and infectious mononucleosis-like
esions, usually require no intervention and are self-
imited, although reduction of immunosuppression may
e considered. Type II polyclonal PTLD usually re-
uires reduction of immunosuppression but has variable
esponse. Type III monomorphic PTLD should be clas-
iﬁed according to the WHO classiﬁcation of lym-
homa, and treatment includes reduction of immuno-
uppression and usually requires chemotherapy. Type
V HL and HL-like PTLD likewise require aggressive
anagement, although there is some controversy in
egard to classiﬁcation of the latter. A recent retro-
pective report from Loma Linda University analyzed
cases of HL-like PTLD with respect to immuno-
henotype, EBV status, clonality, and clinical out-
ome [89]. Although HL-like PTLD was similar
orphologically to classic HL PTLD, the immu-
ophenotype, molecular genetics, and clinical
ourse were more consistent with a monomorphic
-cell PTLD.
The anti-CD20 antibody rituximab has been
hown to be effective in PTLD [90-95]. A multicenter
hase II German study of 17 patients with solid-organ
TLD showed a 53% complete response rate using
ingle agent rituximab with a mean duration of 17.8
onths [93]. A retrospective study of solid-organ
TLD from the University of Pennsylvania found a
8% response rate in 22 patients treated with ritux-
mab with a median duration not reached at 19
onths [95]. In univariate analysis, EBV positivity
redicted response. The authors concluded that
TLD patients requiring therapy beyond reduction of
mmunosuppression should be considered for ritux-
mab, especially with EBV-positive disease, and che-
otherapy should be reserved for those who fail rit-
ximab, have EBV-negative tumors, or need a rapid
esponse.
Infusion of EBV-cytotoxic T cells has also been
tudied in the treatment of PTLD [85,96,97]. In 1
tudy of patients with progressive PTLD unrespon-
ive to conventional treatment, HLA-matched cyto-
oxic T cells were infused with a complete response in
of 8 patients, although responses were mainly in
hose with early, localized, and polyclonal disease [97].
ytokine therapy has also been studied with a multi-
enter phase I-II trial of an anti-interleukin 6 mono- tlonal antibody showing a 41% response rate in early
TLD [98,99].
reatment-Related Myelodysplastic Syndrome
nd Second Leukemia
There is signiﬁcant controversy regarding risk fac-
ors for development of treatment-related myelodysplas-
ic syndrome (tMDS) and second leukemias. tMDS and
econd leukemias in HCT occur almost entirely in the
utologous setting where exposure to certain chemo-
herapeutics (alkylating agents, topoisomerase II inhibi-
ors, and possibly anthracyclines) and total-body irradi-
tion (TBI) appear to be the greatest risk factors
30,100-106].
tMDS and second leukemia are extremely rare
fter allo-HCT (Table 4) [25,27,28,42]. The low in-
idence supports the hypothesis that tMDS and
econd leukemia may be primarily related to pretrans-
lant factors and not to HCT itself. The graft-versus-
arrow effect of allo-HCT likely decreases the risk of
ecipient derived MDS/secondary leukemia [30].
aker et al. [25] reported 4 cases of MDS/AML of
179 allo-HCT patients during the period 1974 to
001. The leukemic clones all originated in host cells
ut were morphologically and cytogenetically differ-
nt from the initial malignancy. A large study from the
ate Effects Working Party of Europe evaluating sec-
nd malignancies in 903 allo-HCT patients observed
ore than 5 years from transplantation reported no
ncidence of second leukemia [28]. However, there
as mention of 1 patient in the database who devel-
ped second leukemia before 5 years of follow-up, but
etails on cell origin were not provided. Witherspoon
t al. [42], from the Fred Hutchinson Cancer Re-
earch Center, reported 6 second leukemias of 1993
llo-HCT for leukemia or aplastic anemia from 1970-
987, with 4 being of donor cell origin.
Given the rarity of second leukemia after allo-
CT, risk factors are likely to remain elusive. The
easons for developing leukemia from host derived
ells may be similar to risk factors identiﬁed in autol-
gous HCT where exposure to prior therapy may lead
o chromosomal damage in progenitor cells that sur-
ive after transplantation. Many mechanisms have
een proposed as possible causes of second leukemia
n donor cells after allo-HCT. Antigenic stimulation
hrough host tissue has shown to be able to transform
onor cells in vivo [107-110]. An unknown factor in
he marrow environment may lead to leukemic trans-
ormation (ie, an oncogenic virus) [107-112]. Preex-
sting genetic factors may certainly be important in
elated donor allo-HCT [113,114]. There is 1 case in
he literature of allo-HCT donor-derived inadvertent
ransplantation of preexisting leukemia [115], and an-
ther case of liver transplant donor-derived acute pro-
yelocytic leukemia presumably from stem cells inhe transplanted organ [116].
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Second Malignancies after allo-HCT 1127econd Solid Malignancies
Epidemiology. Unlike the short latency of PTLD,
SM have a long latency period of multiple years
ollowing allo-HCT. The largest studies report a
.85- to 34-fold increased risk of SSM compared to
he normal population with a median time from allo-
CT to diagnosis of 3.3 to 6.8 years (Table 5) [22,25-
8,31,42]. Most of these studies exclude squamous and
asal cell skin carcinomas, as they are not recorded in
he SEER database. It is important to note that a
lateau has not been reached in long-term follow-up,
nd the cumulative incidence continues to increase.
Curtis et al. [31] reported the largest study to date
f SSM in 1997. A total of 19,229 patients underwent
llogeneic (97.2%) and syngeneic (2.8%) HCT from
35 medical centers (IBMRT and Fred Hutchinson
ancer Research Center) between 1964 and 1992.
he relative risk of SSM was 2.7, and increased to 8.3
or those who survived 10 years. The cumulative
ncidence of new solid malignancies also increased
rom 2.2% at 10 years to 6.7% at 15 years of follow-
p. Signiﬁcantly increased risks by tumor type were
een in bone (RR 13.4), oral cavity (RR 11.1), brain
nd central nervous system (RR 7.6), hepatocellular
RR 7.5), thyroid (RR 6.6), melanoma (RR 5.0), and
onnective tissue (RR 8.0) malignancies.
Risk factors. Several risk factors have been identi-
ed that may contribute to the development of SSM
fter allo-HCT. These include radiation and chemo-
herapy used in primary treatment and conditioning
or allo-HCT, immunodeﬁciency from incomplete re-
overy after allo-HCT, and immune stimulation and
uppression from GVHD [30]. Speciﬁc risk factors
dentiﬁed from the largest studies of second malignan-
ies after allo-HCT are discussed later.
Radiation. Radiation may account for some if not
ost of the long latency seen in SSM after allo-HCT.
he 13th report from the Life Span Study cohort of
urvivors of the atomic bomb in Hiroshima and
agasaki provides more than 5 decades of follow-up
6]. The relationship between radiation dose and ex-
ess solid cancer risk appears to be linear. Approxi-
ately 5% of solid cancer deaths to date have been
ttributed to radiation, and it is estimated that 60%-
0% of radiogenic cancer-related deaths have yet to
ccur. The number of cancer-related deaths continues
o increase in both adults and children, but the risk is
igher in the latter.
The risk of radiation-induced SSM after cancer
reatment is perhaps best described in the pediatric
odgkin disease (HD) literature [13,18-21]. Bhatia et
l. [13] reported long-term follow-up from the Late
ffects Study Group of 1380 children treated for HD.
he cumulative incidence for second solid malignancy
as 7.3% at 20 years, increasing to 23.5% at 30 years.Breast cancer was the most common solid malignancyTa Ba
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Table 5. Studies of Second Solid Malignancy after Allogeneic HCT
Study Setting
Number of
Patients
Median Time to
Solid Malignancy
(Years)
Cumulative
Incidence of New
Second Solid
Malignancy Relative Risk Significant Risk Factors
Gallagher, 2007 (multi-
institution, British
Columbia)
Second solid malignancies after
allogeneic transplant 1985-2003
926 6.8 2.3% at 10 years* 1.85*
Not given for individual
cancer types
-Recipient age at BMT >40
(P  .005)
-Woman donor (P  .0008)
Baker, 2003 (single institution,
U Minnesota)
Second malignancies after
autologous and allogeneic
transplant 1974-2001
3372 (2179 allo) 4.2 (auto and allo) 0.4% at 1 year*
1.2 at 5 years*
2.2 at 10 years*
3.8% 20 years*
(auto and allo)
8.1* (auto and allo)
Oral 10.2
Brain 9.5
Melanoma 8.3
Lung 2.1
Breast 1.5
Colon 1.8
-age >20 years at time of
BMT (RR 2.0); however,
age <10 RR 33.3
Bhatia, 2001 (single institution,
City of Hope)
Second solid malignancies after
autologous and allogeneic
transplant 1976-1998
2129 (1370 allo) 3.3 Cervical
7.6 Oral
10.8 Liver (auto
and allo)
1.6% at 5 years*
6.1% at 10 years*
6.4% allo, 1.6%
auto)
14.9% at 15
years* (auto
and allo)
2.1* (auto and allo)
Liver 27.7
Oral cavity 17.4
Cervical 13.3
-Age < 34 years at time of
BMT (RR 5.3)
Socie, 2000 (multi-institution,
international bone marrow
transplant registry/U Wash)
Second malignancies after
allogeneic transplant for
childhood acute leukemia
(<age 17) 1964-1992
3182 6 0.9% at 5 years*
4.3% at 10 years*
11% at 15 years*
34*
Tongue 2765
Sal. gland 519
Thyroid 125
Melanoma 65
Brain/CNS 46
Bone and Connective tissue
20
-Recipient age <10 years at
transplantation (RR 3.7)
-High-dose TBI (RR 3.1)
-(Chronic mod-severe GVHD
lower risk RR 0.2)
Kolb, 1999 (multi-institution,
Late Effects Working Party-
Europe)
Second malignancies in long-term
survivors (>5 years) after
autologous and allogeneic
transplant before 1986
982 evaluable (903
allo)
NR 3.5% at 10 years
11.5% at 15
years (auto
and allo)
3.8 (auto and allo)
>10-fold for oral, esophagus,
thyroid. skin ca(basal/sq
cell),
>5-fold for Hodgkin
glioblastoma, uterus/cervix
-Older recipient age (RR 1.4)
-Immunosuppressive therapy
-Cyclosporine (RR 1.4)
-Thalidomide (RR 3.4)
Curtis, 1997 (multi-institution,
international bone marrow
transplant registry/U Wash)
Second solid malignancies after
allogeneic and syngeneic
transplant 1964-1992
19,229 (18,696 allo) NR 2.2% at 10 years*
6.7% at 15 years*
2.7*
(8.3 for survivors > 10 years)
Bone 13.4
Oral 11.1
CNS 7.6
Liver 7.5
Thyroid 6.6
Melanoma 5.0
Connective tissue 8.0
-High-dose TBI (RR 2.7-4.4)
-Chronic GVHD (cGVHD)
with oral and skin SCC
(RR 6.0, 22.6)
-Younger recipient age (age
<10, RR 36.6) T.
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Second Malignancies after allo-HCT 1129RR 56.7), followed by thyroid, bone, colorectal, and
astric cancers. Risk factors included younger age at
reatment and radiation based therapy.
Despite the well-described relationship between
adiation and SSM, only 2 of the largest studies of
SM after allo-HCT, both from the IBMRT and Fred
utchinson Cancer Research Center, describe a sig-
iﬁcant association [27,31]. Curtis et al. [31] found a
ighly signiﬁcant dose related 2.7- to 4.4-fold higher
isk with high-dose TBI. Socie et al. [27] reported a
.1-fold risk with high-dose TBI. Notably, 6 of the 9
atients with second brain cancers and 3 of the 5
hyroid cancer patients had received cranial radiation
or treatment or prophylaxis of acute leukemia before
llo-HCT. Other studies of SSM have failed to show
signiﬁcant association. Witherspoon et al. [42] re-
orted a 3.9-fold increased risk of all second malig-
ancies after TBI but this was not signiﬁcant when
ssessing solid malignancies alone. A study from the
niversity of Minnesota by Bhatia et al. [32] showed a
-fold increased risk in patients treated with TBI
hich approached statistical signiﬁcance (P  .08);
owever, a more recent report with 6 more years of
ollow-up gave less conclusive results (RR 1.5, P 
27) [25]. There are multiple possible explanations for
he negative ﬁndings. The large studies did report
igniﬁcantly increased risks of tumors previously at-
ributed to radiation exposure such as head and neck,
one, brain, and thyroid cancers [22,25,26,28,32,42].
one of the studies quantify the amount of pretransplant
xposure to radiation. Also, follow-up is still relatively
hort for most of these studies. Data from the atomic
omb survivor cohort and children treated for HD sug-
est that risk of second solid malignancy after radiation
xposure remains elevated for multiple decades, and
herefore many more radiogenic malignancies may
merge with longer follow-up [6,13,18-21].
Age. There is conﬂicting data regarding the rela-
ionship between age of the recipient at the time of
llo-HCT and the risk of SSM. Some studies support
hat risk is increased in younger recipients [26,27,31].
he analysis from the City of Hope found a 5.3-fold
ncreased risk in recipients less than age 34 at the time
f allo-HCT [26]. Another analysis by Socie et al. [27]
as limited only to children less than age 17, but
eported the highest overall RR of SSM (RR 34). This
ncluded 3 tongue and 2 salivary gland cancers, which
re extremely rare in children. Children ages 0-9
howed a 3.7-fold greater risk than those between the
ges of 10 and 16. Curtis et al. [31] reported an RR of
6.6 for recipients less than age 10 at the time of
llo-HCT.
The explanation for a possibly increased risk in
oung children, especially less than age 10, may be
ultifactorial. As discussed above, radiogenic tumors
ave a long latency, and therefore children may expe-rience increased incidence of SSM simply because ofTa W
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T. Lowe et al.1130onger life expectancy and follow-up. The literature
n second breast malignancy after treatment for child-
ood HD also suggests that radiation may have in-
reased carcinogenic potential on proliferating tissue
n young patients [13,18-21].
Conversely, other studies suggest that older age at
llo-HCT increases the risk of SSM [22,25,28]. Gal-
agher reported that age 40 was a signiﬁcant risk
actor; however, only 2% of the patients in the study
ohort were18 years old [22]. Baker et al. [25] found
n increased risk in those more than age 20 years (RR
.0), although subgroup analysis suggested the highest
isk was actually among recipients 10 years old (RR
3). The second malignancies included rare pediatric
umors such as melanoma, renal cell, breast, and pa-
otid cancer. Kolb et al. [28] observed a slightly in-
reased risk with older age on a continuum at allo-
CT transplant (RR 1.4). The authors concluded that
he risk for GVHD increased with age, and may in-
rease second tumor risk.
GVHD/Immunosupressants. None of the large stud-
es of SSM after allo-HCT report an overall associa-
ion with GVHD. In fact, Socie et al. [27], in 2000,
bserved an unexpected decrease in risk with GVHD.
otably, most of these studies excluded nonmelanoma
kin cancer in the multivariate analysis as these are not
eported in the SEER database. The IBMRT and
nvestigators from the Fred Hutchinson Cancer Re-
earch Center did ﬁnd a 6-fold higher risk when eval-
ating separately for onset of oral and skin SCC [31].
he report by Bhatia et al. [26] from our institution
ound that all 6 patients with nonmelanoma skin can-
er had developed GVHD. Many of the studies also
ound an association between use of immunosupres-
ants for GVHD and risk of second solid tumors.
itherspoon et al. [42] observed a 4.3-fold risk with
he use of ATG in acute GVHD (aGVHD). The
eport from the Late Effects Working Party of
urope showed a 1.4-fold risk for cyclosporine [28].
verall, it appears that immunosuppression rather
han GVHD directly, except in nonmelanoma skin
ancers as discussed below, increase the risk of SSM
fter allo-HCT.
Viruses. Viruses may play a small role in some
SM. Three of the large studies found a 7.5- to 125-
old increased risk of hepatocellular carcinoma (HCC)
fter allo-HCT, although this translates to only 6
atients of more than 22,000 allo-HCT recipients
26,31,42]. Both patients from our institution had a
istory of chronic hepatitis C, but viral status was not
eported in the other studies. EBV has been impli-
ated in a case report of an early second gastric car-
inoma [117]. Human papillomavirus (HPV) may also
lay a role in SCC of the skin and mucous membranes
118]. Four patients in the cohort from City of Hope
ad cervical cancer attributed to HPV infection (RR
3.3) [26]. bNonmelanoma skin cancer. Many of the studies of
econd malignancies after allo-HCT exclude risk anal-
sis for nonmelanoma SCC and basal cell carcinoma
BCC) skin cancer, as they are not reported in the
EER database. A recent report on second SCC and
CC of the skin and mucous membranes from the
red Hutchinson Cancer Research Center and afﬁli-
tes contained follow-up on 4810 patients who under-
ent allo-HCT between 1969 and 2003 and survived
t least 100 days [23]. Two hundred thirty-seven pa-
ients developed at least 1 cancer (158 BCC, median
.9 years from allo-HCT; 95 SCC, median 6.3 years
rom allo-HCT). Twenty-year cumulative incidence
as 6.5% for BSC for and 3.4% for SCC. The risk for
CC was signiﬁcantly increased with TBI (P  .003),
nd was strongest for recipients 18 years old at
llo-HCT (P  .02). The risk of SCC was signiﬁ-
antly increased with aGVHD grades II-IV (P  .02)
nd cGVHD (P  .001), whereas the risk of BCC was
ncreased with cGVHD (no mention of grade, P .01).
ONCLUSIONS
HCT may prolong life and cure many patients
uffering from otherwise fatal diseases. Most of the
ransplant literature concentrates on reporting short-
erm complications such as infection and GVHD.
owever, the growing population of long-term survi-
ors has led to our realization of multiple long-term
omplications including the risk of second malignan-
ies. There are multiple factors that may be involved
n the development of second malignancies including
ytotoxic chemotherapy, radiation, immunosuppres-
ive therapy, immune stimulation and immune sup-
ression from GVHD, antigenic stimulation, onco-
enic virus activity, and genetic predisposition [30].
ompared to the autologous setting, allo-HCT car-
ies a much higher risk of PTLD, but tMDS and
econd leukemias are extremely rare. Both autologous
nd allo-HCT carry increased risks for SSM.
PTLD after allo-HCT usually has a short latency
eriod, with the majority of cases occurring within the
rst year, although EBV negative PTLD may increase
n late-onset PTLD. PTLD encompasses a range of
enign polyclonal hyperplasias to malignant monoclo-
al lymphomas, and standard treatment options in-
lude reduction of immunosuppression, cytotoxic che-
otherapy, and use of rituximab. High-risk patients,
uch as those given thymoglobulin, should be moni-
ored for EBV reactivation with EBV quantitative
CR. Rituximab appears to have efﬁcacy in treating
BV reactivation and thereby preventing EBV-asso-
iated PTLD.
The latency period for solid malignancies is rela-
ively long, usually being multiple years. Most nota-
ly, a plateau has not been reached in any of the
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Second Malignancies after allo-HCT 1131argest long-term studies. Data from the cohort of
tomic bomb survivors suggests that such risk contin-
es to be elevated 50 years from exposure [6]. As we
btain further follow-up, more solid tumors are likely
o emerge. Hence, systematic, prospective follow-up,
igilant screening processes, and well-maintained sur-
ivorship clinics and databases are absolute necessities.
uch entities should be included in the infrastructure
f individual transplant centers and networks, with
andatory periodic reporting of second malignancy
ncidences. Primary care physicians may often have
he most continuity years from allo-HCT, and must
e aware of the continued risk of second malignancy.
he highest risk cancers identiﬁed across the largest
tudies include cancers of the skin, oral cavity,
hyroid, brain, and central nervous system, connective
issue, and bone. Hepatitis C patients and women
ffected with cervical HPV appear to be at particular
isk for are hepatocellular carcinoma and cervical car-
inoma, respectively.
There are long-term follow-up guidelines for sur-
ivors of childhood, adolescent, and young adult can-
ers based on type of cancers and exposures published
y the Children’s Oncology Group [119]. The mini-
um follow-up guidelines for all allo-HCT recipients
hould include yearly history and comprehensive
hysicals. Special attention should be made to the
rgan systems at highest risk for second malignancy
ncluding the skin and oral cavity, thyroid, lymphatic,
eurologic, musculoskeletal, and gynecologic. Breast
nd colon cancer risk may also be slightly increased
nd therefore current screening guidelines for the
eneral population should be strictly followed. Fur-
her research is necessary to evaluate whether the
creening age guidelines for colonoscopy and mam-
ography after allo-HCT should be lowered.
Continued research is required to attempt to
uantify risk based not only on transplant factors but
retransplant exposures as well. Primary care and
ransplant physicians alike must be aware of the risk of
econd malignancies after HCT. Guidelines for all
CT recipients in regard to screening and prevention
f second malignancies based on available evidence
nd expert opinion should be developed, so physicians
an provide state of the art counsel and care for the
eneﬁt of our patients.
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